Trial Profile
Neutrophil Elastase Inhibition as Adjunctive Therapy to Improve Glucometabolic Variables in Overweight and Obese, Insulin-Resistant Type 2 Diabetic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Alvelestat (Primary) ; Metformin; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 20 Jun 2019 Status changed from active, no longer recruiting to completed.
- 17 May 2018 Planned End Date changed from 1 Mar 2019 to 1 May 2019.
- 17 May 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2019.